FindTrial
Sign In

High Dose Therapy in Poor-Risk Primary Breast Cancer

High Dose Therapy in Poor-Risk Primary Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN52623943
Enrollment
Unknown
Registered
2002-08-19
Start date
1999-01-01
Completion date
Unknown
Last updated
2020-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Breast

Interventions

1. Regimen A: Chemotherapy, 5-fluorouracil, epirubicin and cyclophosphamide (FEC), one 3 week cycle, then FEC repeated every 4 weeks for five cycles. 2. Regimen B: Chemotherapy, FEC o

Sponsors

Amgen Limited (UK)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Complete prior resection of tumour and axillary node clearance 2. Histologically proven T1-T4 primary breast cancer with at least four involved nodes in the axilla 3. Adequate local therapy as defined in the protocol 4. Aged <60 years 5. No previous malignancy or evidence of metastatic disease 6. Fit to receive treatment

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026